VEGF expression, microvessel density and dendritic cell decrease in thyroid cancer.

Area of Science:

• Oncology
• Immunology
• Angiogenesis Research

Background:

• Thyroid cancer is a common malignancy, particularly in adults aged 20-50.
• Vascular endothelial growth factor (VEGF) and dendritic cells are implicated in thyroid tumor development.
• Understanding the interplay between VEGF, neovascularization, and immune cells is crucial for thyroid cancer research.

Purpose of the Study:

• To investigate the expression of VEGF and microvessel density (MVD) in different thyroid carcinoma types.
• To evaluate the impact of VEGF expression in thyroid tumor cells on dendritic cells.
• To correlate VEGF and MVD with patient survival in papillary thyroid carcinoma.

Main Methods:

• Immunohistochemical analysis of 65 thyroid carcinoma patients (papillary, oncocytic, follicular, anaplastic).
• Antibodies used: VEGF, CD1a, CD83, S100, and CD31 (for MVD).
• Statistical analysis to compare VEGF expression, MVD, and dendritic cell populations across cancer types and correlate with survival.

Main Results:

• VEGF expression was significantly higher in papillary thyroid carcinoma (PTC) compared to anaplastic thyroid carcinoma (ATC).
• Tumor border MVD (CD31+) was significantly higher in PTC than follicular thyroid carcinoma (FTC).
• In oncocytic carcinoma (OC), increased vessel count correlated positively with CD83+ dendritic cells in tumor stroma. No significant association was found between VEGF/MVD and PTC patient survival.

Conclusions:

• VEGF expression in thyroid cancer cells can drive tumor neovascularization.
• VEGF may play a role in suppressing dendritic cell function within the tumor microenvironment.
• Further research is needed to elucidate the full impact of VEGF and immune cell interactions on thyroid cancer progression.